Medtech the Q4 star at J&J, but overall results seen as 'largely disappointing'
This article was originally published in Scrip
Johnson & Johnson signalled the start of the earnings season on 22 January, with its fourth quarter and full-year 2012 results showing that its medical device and diagnostics division outperformed its pharmaceutical and consumer businesses.
You may also be interested in...
Increasing savvy around cybersecurity issues is driving regulators and trade groups to update their approach to the area, speakers from the US FDA and the American Medical Association said at this week’s FDA/CMS Summit.
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.